11th April 2016

Preventive migraine treatment on the horizon

Hopes rise with latest trial results of breakthrough drug

medicinesThe outlook for the eight million people living with migraine in the UK could change in the near future thanks to new research and drug developments from a number of pharmaceutical companies. This could mean new preventive treatment options, which are designed to reduce the frequency and severity of migraine attacks.

The four companies, Teva, Amgen, Eli lily and Alder, are in the latter trial stages of investigating medicines that target a chemical known as calcitonin gene-related peptide or CGRP; it helps control the width of blood vessels and plays an important role in managing pain. The preventive treatment options are being targeted at episodic and chronic migraine as well as indications for cluster headache.

“This is a huge development for migraine sufferers. There is no current specific treatment that has been developed for migraine. The research has now come to a point where we understand the condition enough that we have worked out how to treat it. For a group of people who have never had a proper treatment, this is fantastic news. We have four companies charging along to develop this drug, which can only be a good thing. Competition can only push people along and push down prices.” Professor Peter Goadsby, trustee of The Migraine Trust
“These developments could prove life-changing for many migraine sufferers. An increase in the number of treatment options is a very exciting prospect, and could reduce the burden of migraine, including its impact on sufferers’ personal and professional lives.” Hannah Verghese, Advocacy and Policy Manager of The Migraine Trust



Other news